Seikagaku Corporation · TSE:4548
Seikagaku — Q2 FY2024 Earnings Presentation
19 slides from Seikagaku's earnings presentation, Aug 5, 2024
Slide 1: Financial Results for the 2nd Quarter of Fiscal Year 2024
Exploring the Innovative Promise of Glycoscience Financial Results for the 2nd Quarter of Fiscal Year 2024 （TSE：4548）
Slide 2: Contents
Exploring the Innovative Contents Promise of Glycoscience 2Q of FY 2024 Results P3-7 Overview Domestic Pharmaceuticals Overseas Pharmaceuticals Bulk Products / CDMO, Royalty, LAL Business Research and Development P8-13 SI-6603 (Lumbar disc herniation) SI-614 (Dry Eye) SI-722 (Inter
Slide 3: 2Q of FY 2024 Results
Exploring the Innovative Promise of Glycoscience 2Q of FY 2024 Results 3
Slide 4: Overview for 2Q of FY 2024
Exploring the Innovative Overview for 2Q of FY 2024 Promise of Glycoscience Net sales: Up 11.9% year on year on increases in royalty income and overseas sales in the LAL business Income: Net income attributable to owners of parent down 8.1% year on year due mainly to yen appreciation toward the
Slide 5: Domestic Pharmaceuticals
2Q of FY 2024 Results Exploring the Innovative Promise of Glycoscience Domestic Pharmaceuticals Net sales down 15.6％ year on year due to lower sales of ARTZ, a joint function improvement agent for knee osteoarthritis, and the OPEGAN series of ophthalmic viscoelastic devices ARTZ（Joint-function imp
Slide 6: Overseas Pharmaceuticals
2Q of FY 2024 Results Exploring the Innovative Promise of Glycoscience Overseas Pharmaceuticals Net sales up 8.9% year on year due mainly to higher sales of Gel-One and SUPARTZ FX, viscosupplements for the treatment of knee osteoarthritis for the U.S. market Sales Comparison Products for the U.S.
Slide 7: Bulk Products / CDMO, Royalty, LAL Business
2Q of FY 2024 Results Exploring the Innovative Promise of Glycoscience Bulk Products / CDMO, Royalty, LAL Business Bulk Products / CDMO LAL Business Foreign exchange impact : approx. +138million yen Foreign exchange impact : approx. +625million yen Net sales were at the prior-year level because of
Slide 8: Research and Development
Exploring the Innovative Promise of Glycoscience Research and Development 8
Slide 9: Pipeline List
Research and Development Exploring the Innovative Promise of Glycoscience Pipeline List Development code/ Appli- Market PI PII PIII cation approval Indication (Product name) SI-6603 SI-6603 Lumbar Disk Herniation （Condoliase） US SI-614 SI-614 Dry eye （Modified Hyaluronate） US Target Market SI-613 SI
Slide 10: SI-6603 (Treatment for Lumbar Disc Herniation)
Research and Development Exploring the Innovative Promise of Glycoscience SI-6603 (Treatment for Lumbar Disc Herniation) Biologics License Application for SI-6603 accepted by the U.S. Food and Drug Administration (FDA) Proceed with a response to regulatory review in order to obtain approval Developm
Slide 11: SI-614 (Dry Eye)
Research and Development Exploring the Innovative Promise of Glycoscience SI-614 (Dry Eye) Received the results from a Phase III study in the U.S. Currently considering the future development policy Development status Administration image ▶ Phase III study in the U.S. • Statistically significant imp
Slide 12: SI-722 (Interstitial cystitis and bladder pain syndrome)
Research and Development Exploring the Innovative Promise of Glycoscience SI-722 (Interstitial cystitis and bladder pain syndrome) Subject enrollment for Phase I/II studies in the U.S. completed Currently considering the future development policy Administration image Development status ▶ Phase I/II
Slide 13: SI-449 (Adhesion Barrier / Medical Device)
Research and Development Exploring the Innovative Promise of Glycoscience SI-449 (Adhesion Barrier / Medical Device) Received the results from pivotal and pilot studies in Japan Proceed with preparations for an application for approval Development status ▶ Japan pivotal study (field of gastroenterol
Slide 14: Other Topics
Exploring the Innovative Promise of Glycoscience Other Topics 14
Slide 15: Approval in China of MucoUp, a Submucosal Injection Agent for Endoscopic Surgery
Other Topics Approval in China of MucoUpⓇ, Exploring the Innovative Promise of Glycoscience a Submucosal Injection Agent for Endoscopic Surgery Approval notice received from the National Medical Products Administration (“NMPA”) of China (dated Sept. 30, 2024) Distribution agreement for China con
Slide 16: Appendix
Exploring the Innovative Promise of Glycoscience Appendix 16
Slide 17: FY2024 Forecasts Overview
Appendix Exploring the Innovative Promise of Glycoscience FY2024 Forecasts Overview Net sales：Projected year-on-year increase from higher royalty income Operating Income：Projected increase due to the revenue growth and lower R&D expenses Ordinary Income：Projected increase due to the revenue gr
Slide 18: Basic Policy on Profit Distribution
Appendix Exploring the Innovative Promise of Glycoscience Basic Policy on Profit Distribution Make investments for sustained profit growth and corporate value enhancement and pay stable dividends Shareholder returns Consider dividend increases with ¥26 per share as a guideline, taking into account
Slide 19: Cautionary Notes
■Cautionary Notes This material contains forward-looking statements regarding future management strategies or performance forecasts. These descriptions are based on judgments derived from information that is currently available to Seikagaku and are subject to risk and uncertainty. Actual results and